Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2000-07-27
2009-12-15
Mondesi, Robert B (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S234100, C424S190100, C424S184100, C530S300000, C530S350000, C536S023100, C536S023700, C435S069100, C435S069700
Reexamination Certificate
active
07632516
ABSTRACT:
The invention provides BASB115 polypeptides and polynucleotides encoding BASB115 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
REFERENCES:
patent: 6632636 (2003-10-01), Lagace et al.
patent: 6673910 (2004-01-01), Breton
patent: WO 00/78968 (2000-12-01), None
Rudinger et al, in “Peptide Hormones”, edited by Parsons, J.A., University Park Press, Jun. 1976).
Burgess et al., The Journal of Cell Biology, 111:2129-2138, 1990.
Lazar et al., Molecular and Cellular Biology, 8(3): 1247-1252, 1988.
Jobling et al Mol. Microbiol. 1991, 5(7): 1755-67.
McMichael, 2000, Microbes and Infection 2; 561-568 ).
Christensen et al Clin Diagn Lab Immunol. Nov. 1996; 3(6): 717-21.
Current Protocols in Immunology, 1997 unit 9.7.5,/9-7-16/9-7-19-.
Reece et al, J. Immunological methods. 1994, vol. 172, p. 241-254-.
Arnon et al FASEB J. Nov. 1992; 6(14): 3265-74.
Molecular Immunol. 35, 1998, pp. 73-81.
Roitt et al, 1998, Immunology, 4th ed, Mosby, London, (p. 7.7-7.8).
Herbert et al. (The Dictionary of Immunology, Academic Press, 4th edition, 1995, p. 58).
Greenspan et al., (Nature Biotechnology 7:936-937 (1999).
Coleman et al. (Research in Immunology, 1994; 145(1): 33-36).
Abaza et al. (Journal of Protein Chemistry, vol. 11, No. 5, 1992, pp. 433-444.
Bowie et al (Science, 1990, 257:1306-1310).
International Search Report for PCT/EP/ 00/07294.
EPO Communication Pursuant to Article 96(2) EPC, Aug. 4, 2004.
Myers, Lisa E., et al., “The Transferrin Binding Protein B. ofMoraxella catarrhalisElicits Bactericidal Antibodies and Is a Potential Vaccine Antigen”, Infection and Immunity, Sep. 1998, 66(9); 4183-4192.
Klein, 1994, “Otitis Media,” Clinical Infectious Diseases 19:823-833.
Murphy, 1996, “Branhamella catarrhalis; Epidemiology, Surface Antigenic Structure, and Immune Response,” Microbiological Reviews 60(2):267-279.
Dickinson et al., 1988, “Restriction Fragment Mapping ofBranhamella catarrhalis: A New Tool for Studying the Epidemiololgy of This Middle Ear Pathogen,” The Journal of Infectious Diseases 158(1):205-208.
Fadan et al., 1991, “Nasopharyngeal Flora in the first Three Years of Life In Normal and Otitis-Prone Children,” Ann Otol Rhinol Laryngol 100:612-615.
Fadan et al., 1994, “Epidemiology ofMoraxella catarrhalisin Children during the first 2 Years of Life: Relationship to Otitis Media,” The Journal of Infectious Diseases 169:1312-1317.
Leach et al., 1994, “Bacterial Colonization of the Nasopharynx Predicts very early onset and Persistence of Otitis Media in Australian Aboriginal Infants,” Pediatric Infectious Disease Journal 13(11):983-989.
Prellner et al., 1984, “Nasopharyngeal Carriage of Bacteria in Otitis-Prone and Non-otitis-prone Children in Day-Care Centres,” Acta Otolaryngol (Stockh) 98:343-350.
Stenfors et al., 1992, “Abundant Attachment of Bacteria to Nasopharyngeal Epithelium in Otitis-Prone Children,” The Journal of Infectious Diseases 165:1148-1150.
Stenfors et al., 1993, “Secretory IgA-, IgG- and C3b-coated Bacteria in the Nasopharynx of Otitis-Prone and Non-Otitis-Prone Children,” Acta Otolaryngol (Stockh) 113:191-195.
Chapman et al., 1985, “Development of Bactericidal Antibody DuringBranhamella catarrhalisInfection,” The Journal of Infectious Diseases 151(5):878-882.
Hol et al., 1993, “Complement Resistance inBranhamella(Moraxella)catarrhalis,” Lanclet 341:1281.
Jordan et al., 1990, “A Comparison of Serum Bactericidal Activity and Phenotypic Characteristics of Bacteremic, Pneumonia-Causing Strains, and Colonizing Strains ofBranhamella catarrhalis,” The American Journal of Medicine 88(5A):28S-32S.
Sethi et al., 1995, “Serum Antibodies to Outer Membrane Proteins (OMPs) ofMoraxella(Branhamella)catarrhalisin Patients with Bronchiectasis: Identification of OMP B1 as an Important Antigen,” Infection and Immunity 63(4):1516-1520.
Ellis, R. W., “New Technology for Making Vaccines,” Chapter 29 ofVaccines, Plotkin et al. (eds) published by W.B. Saunders Company (Philadelphia) 1988 pp. 568-575.
Van De Loo, Frank J., et al., “An Oleate 12-hydroxylase fromRicinus communisL. is a Fatty Acyl Desaturase Homolog,”Proc, Natl. Acad. Sc., vol. 92, pp. 6743-6747, Jul. 1995.
Attwood, T. K., “The Babel of Bioinformatics,”Science, vol. 290, pp. 471-473, Oct. 20. 2000.
Non-Final Office Action Summary, Dated Jul. 1, 2005 for U.S. Appl. No. 10/048,574, File Date: Jan. 23, 2002.
Response to Non-Final Office Action, Dated Jul. 1, 2005 for U.S. Appl. No. 10/048,574, File Date: Jan. 23, 2002.
Non-Final Office Action Summary, Dated May 17, 2006 for U.S. Appl. No. 10/048,393, File Date: Apr. 29, 2002.
Dillner et al., “Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen,” Aug. 1984, Proc. Natl. Acad. Sci. USA, vol. 81, pp. 4652-4656.
Geysen et al., “Small peptides induce antibodies with a sequence and structural requirement for binding antigen comparable to antibodies raised against the native protein,” Jan. 1985, Proc. Natl. Acad. Sci. USA, vol. 82, pp. 178-182.
Shinnick et al., “Synthetic Peptide Immunogens As Vaccines,” 1983, Ann. Rev. Microbiol., vol. 37, pp. 425-446.
Niman et al., “Generation of protein-reactive antibodies by short peptides is an event of high frequency: Implications for the structural basis of immune recognition,” Aug. 1983, Proc. Natl. Acad. Sci. USA, vol. 80, pp. 4949-4953.
Baskar Padma V
GlaxoSmithKline Biologicals S.A.
Mondesi Robert B
Seed IP Law Group PLLC
LandOfFree
Moraxella catarrhalis BASB115 polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Moraxella catarrhalis BASB115 polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Moraxella catarrhalis BASB115 polypeptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4116644